Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Interest Expense

Cost of servicing the company's debt during the period.

Vicore Pharma Holding ABNASDAQ: VCRE

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense declines year over year

Q2 FY2026 interest expense of SEK 103 fell 100.0% year over year, behind the -77.5% change in trailing-twelve-month interest expense. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +95.7% a year.

Context

  • Interest expense amounted to 1.6% of revenue in FY2025, up 1.6 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -77.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 103-100.0% QoQ
Last fiscal yearDec 2025
SEK 60K+650.0% YoY
LTMJun 2026
SEK 9.19M-77.5% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+650.0%——
3-year CAGR+95.7%——
5-year CAGR——
10-year CAGR——

Interest Expense history

SEK · from the income statement

Latest · FY2025
60K SEK
Year-over-year change
+650.0%

Interest Expense vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -77.5% is the lowest of 2, against a peer median of +50.6%.
  • Interest expense amounts to 691.0% of revenue for VCRE, versus a peer median of 5.9%.
VCRE Competitors
Interest Expense for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LQDALiquidia CorporationLTM Jun 2026$26.63M USD+50.6%+117.8%5.9%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 9.19M SEK-77.5%+95.7%691.0%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+50.6%+117.8%5.9%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.